Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
542 questions in 42 reviews · Skin
current versionsNo studies 542 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tetracycline vs placebo HRQOL ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Tetracycline vs placebo Time needed until improvement of the skin lesions ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Tetracycline vs placebo Duration of remission ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Doxycycline 40 mg vs placebo HRQOL ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Doxycycline 40 mg vs placebo Participant‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Doxycycline 40 mg vs placebo Duration of remission ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Azithromycin vs doxycycline 100 mg HRQOL ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Azithromycin vs doxycycline 100 mg Physician‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Azithromycin vs doxycycline 100 mg Assessment of erythema or telangiectasia ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Azithromycin vs doxycycline 100 mg Time needed until improvement of the skin lesions ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Doxycycline 40 mg + metronidazole 1% gel vs doxycycline 100 mg + metronidazole 1% gel HRQOL ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Azelaic acid vs placebo HRQOL ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Doxycycline 40 mg + metronidazole 1% gel vs doxycycline 100 mg + metronidazole 1% gel Participant‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Doxycycline 40 mg + metronidazole 1% gel vs doxycycline 100 mg + metronidazole 1% gel Duration of remission ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Doxycycline 40 mg + azelaic acid gel vs doxycycline 40 mg + metronidazole gel HRQOL ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Ethinyl estradiol 35 μg + cyproterone acetate 2 mg vs ethinyl estradiol 30 μg + desogestrel 0.15 mg Participant‐reported improvement of hirsutism ‐ not measured · patients with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Ethinyl estradiol 35 μg + cyproterone acetate 2 mg vs ethinyl estradiol 30 μg + desogestrel 0.15 mg Change in health‐related quality of life (HRQOL) ‐ not measured · patients with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg Change in BMI ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg Improvement of other clinical signs of hyperandrogenism ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Spironolactone 100 mg vs placebo Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Spironolactone 100 mg vs placebo Change in BMI ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Spironolactone 100 mg vs placebo Improvement of other clinical signs of hyperandrogenism ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Finasteride 5 mg to 7.5 mg vs placebo Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Finasteride 5 mg to 7.5 mg vs placebo Improvement of other clinical signs of hyperandrogenism ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Metformin 500 mg to 2550 mg per day vs placebo Participant‐reported improvement of hirsutism ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Metformin 500 mg to 2550 mg per day vs placebo Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Metformin 500 mg to 2550 mg per day vs placebo Improvement of other clinical signs of hyperandrogenism ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Finasteride 5 mg vs spironolactone 100 mg Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Finasteride 5 mg vs spironolactone 100 mg Change in BMI ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Finasteride 5 mg vs spironolactone 100 mg Improvement of other clinical signs of hyperandrogenism ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Flutamide 250 mg once to twice daily vs metformin 1275 mg to 1700 mg per day Participant‐reported improvement of hirsutism ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Flutamide 250 mg once to twice daily vs metformin 1275 mg to 1700 mg per day Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Finasteride 5 mg vs flutamide 250 mg once to b.i.d. Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Finasteride 5 mg vs flutamide 250 mg once to b.i.d. Change in BMI ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Flutamide 250 mg b.i.d. vs placebo Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Any topical or systemic intervention vs Placebo, no treatment, or another intervention Outcome NR · People with erosive anogenital (genital) lichen planus Interventions for erosive lichen planus affecting mucosal sites (2012) · Cochrane | None of the included studies assessed the effectiveness of treatments of genital ELP; no evidence was found for genital ELP. | 0 studies | No studies |
Any topical or systemic intervention (topical/systemic steroids, ciclosporin, tacrolimus, retinoids, anti-malarials, biologics, phototherapy, surgery) vs Placebo, no treatment, another active intervention, or a different dose of the same intervention Eating a normally varied diet · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions Interventions for erosive lichen planus affecting mucosal sites (2012) · Cochrane | No studies reported this outcome. | 0 studies | No studies |
Any topical or systemic intervention (topical/systemic steroids, ciclosporin, tacrolimus, retinoids, anti-malarials, biologics, phototherapy, surgery) vs Placebo, no treatment, another active intervention, or a different dose of the same intervention Restoration of sexual activity · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions Interventions for erosive lichen planus affecting mucosal sites (2012) · Cochrane | None of the included studies assessed the effectiveness of treatments of genital ELP; thus, this outcome was not reported. | 0 studies | No studies |
Any topical or systemic intervention (topical/systemic steroids, ciclosporin, tacrolimus, retinoids, anti-malarials, biologics, phototherapy, surgery) vs Placebo, no treatment, another active intervention, or a different dose of the same intervention Reduction in number of flares · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions Interventions for erosive lichen planus affecting mucosal sites (2012) · Cochrane | No studies reported this outcome. | 0 studies | No studies |
Any topical or systemic intervention vs Placebo, no treatment, or another intervention Outcome NR · People with erosive oesophageal lichen planus Interventions for erosive lichen planus affecting mucosal sites (2012) · Cochrane | None of the studies involved oesophageal disease; hence, no evidence was found for the treatment of oesophageal ELP. | 0 studies | No studies |
Any topical or systemic intervention (topical/systemic steroids, ciclosporin, tacrolimus, retinoids, anti-malarials, biologics, phototherapy, surgery) vs Placebo, no treatment, another active intervention, or a different dose of the same intervention Reduction in severity of flares · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions Interventions for erosive lichen planus affecting mucosal sites (2012) · Cochrane | No studies reported this outcome. | 0 studies | No studies |